Healthcare

· A global distribution agreement with Henry Schein is in place, with first shipments contingent on FDA clearance.

The agreement follows laboratory accreditation milestones completed in late 2025 and brings the company closer to the phased rollout it has been working toward across its suite of blood-based diagnostic products.

Biome Australia reported record sales revenue of AUD 23.9 million for FY26, a 30% increase on the prior year, extending a multi-year run of strong top-line growth. The company added roughly AUD 5.5 million of new sales during the year, while international revenue rose …

In its first half of FY26, reported in late February 2026, SomnoMed lifted revenue 13% to AAUD 60.7 million, from AAUD 53.7 million a year earlier, while EBITDA rose 35% to AAUD 7.8 million as margins expanded around 200 basis points to 13%. However, …

Vectus Biosystems (ASX:VBS) is advancing a more focused clinical and commercial strategy around its lead antifibrotic drug candidate, VB0004, while strengthening leadership, funding and regulatory capabilities.

Clarity Pharmaceuticals Limited (ASX:CU6) remained in investor focus within the Australian healthcare sector, with shares trading at AUD 2.38, up 1.71% or AUD 0.040 at the time of writing on 28 August 2026. The movement places attention back on the clinical-stage radiopharmaceutical company as …

Mesoblast Limited (ASX:MSB) remained in investor focus within the Australian healthcare sector, with shares trading at AUD 2.42, up 0.21% or AUD 0.005 at the time of writing on 28 August 2026. The company entered the spotlight after releasing its FY26 financial results and …